ADMA Deadline Alert: Levi & Korsinsky Reminds ADMA BIOLOGICS, INC. (ADMA) Investors of Securities Class Action Deadline on August 10, 2026

ADMA Biologics allegedly used channel stuffing to inflate ASCENIV revenues by millions, turning reported 20% growth into an estimated 3% decline, according to a new securities class action ADMA Biologics allegedly used channel stuffing to inflate ASCENIV revenues by millions, turning reported 20% growth into an estimated 3% decline, according to a new securities class action

GlobeNewsWire • 11 hours ago

ADMA Alert: ADMA Biologics Investors may have been Misled about Alleged Channel Stuffing – Contact BFA Law about the Pending Securities Fraud Class Action

NEW YORK, June 22, 2026 (GLOBE NEWSWIRE) -- A securities fraud class action lawsuit has been filed on behalf of ADMA Biologics investors after its stock plummeted 29% due to Culper Research channel stuffing claims, potentially violating federal securities laws. Leading securities law firm  Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against ADMA Biologics, Inc. (NASDAQ:ADMA) and certain of the Company's senior executives for securities fraud after its significant stock drop resulting from potential violations of the federal securities laws.

GlobeNewsWire • 14 hours ago

ADMA Biologics, Inc. Class Action Lawsuit Seeks Recovery for Investors; August 10, 2026, Deadline - Contact Kessler Topaz Meltzer & Check, LLP

Did you buy ADMA securities between August 9, 2024 and March 25, 2026 ? Affected ADMA Investor Summary Who: ADMA Biologics, Inc. ( NASDAQ: ADMA ) What: Securities fraud class action lawsuit filed Class Period: August 9, 2024 through March 25, 2026 Deadline to Seek Lead Plaintiff Status: August 10, 2026 Key Lawsuit Allegations: Material misstatements and/or omissions concerning the company's revenues and internal controls.

GlobeNewsWire • 3 hours ago

Bronstein, Gewirtz & Grossman LLC Urges ADMA Biologics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

New York, New York--(Newsfile Corp. - June 22, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against ADMA Biologics, Inc. (NASDAQ: ADMA) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired ADMA securities between August 9, 2024 and March 25, 2026, both dates inclusive (the "Class Period").

Newsfile Corp • 9 hours ago

ADMA Biologics, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline

New York, New York and New Orleans, Louisiana--(Newsfile Corp. - June 22, 2026) - Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in ADMA Biologics, Inc. ("ADMA" or the "Company") (NASDAQ: ADMA) of a class action securities lawsuit.

Newsfile Corp • 7 hours ago

ADMA Biologics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - ADMA

LOS ANGELES, June 22, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against ADMA Biologics, Inc. ("ADMA" or "the Company") (NASDAQ: ADMA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of ADMA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments.

PRNewsWire • 17 hours ago

INVESTOR ALERT: ADMA Biologics, Inc. (ADMA) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces

SAN DIEGO--(BUSINESS WIRE)---- $ADMA #ADMA--The case alleges ADMA Biologics and certain of its executives made false and/or misleading statements to investors.

Business Wire • Jun 21, 2026

ADMA Investors Have Opportunity to Lead ADMA Biologics, Inc. Securities Fraud Lawsuit Filed by The Rosen Law Firm

NEW YORK, June 21, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ADMA Biologics, Inc. (NASDAQ: ADMA) between August 9, 2024 and March 25, 2026, both dates inclusive (the "Class Period"), of the important August 10, 2026 lead plaintiff deadline in the securities class action first filed by the Firm. So what: If you purchased ADMA Biologics securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

PRNewsWire • Jun 21, 2026

3 Biotech Firms With Major Potential Catalysts in the Coming Months

As Big Pharma braces for a looming patent cliff that threatens billions in revenue, a different group of companies is chasing the opposite story: a single breakthrough that could define their future. For these smaller players, one strong trial readout or FDA approval can mean the difference between a breakout and a bust.

MarketBeat • Jun 21, 2026

ROSEN, THE FIRST FILING FIRM, Encourages ADMA Biologics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - ADMA

New York, New York--(Newsfile Corp. - June 20, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ADMA Biologics, Inc. (NASDAQ: ADMA) between August 9, 2024 and March 25, 2026, both dates inclusive (the "Class Period"), of the important August 10, 2026 lead plaintiff deadline in the securities class action first filed by the Firm. SO WHAT: If you purchased ADMA Biologics securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

Newsfile Corp • Jun 20, 2026